N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.
MYCN amplification and overexpression are common in neuroendocrine prostate cancer (NEPC). However, the impact of aberrant N-Myc expression in prostate tumorigenesis and the cellular origin of NEPC have not been established. We define N-Myc and activated AKT1 as oncogenic components sufficient to transform human prostate epithelial cells to prostate adenocarcinoma and NEPC with phenotypic and molecular features of aggressive, late-stage human disease. We directly show that prostate adenocarcinoma and NEPC can arise from a common epithelial clone. Further, N-Myc is required for tumor maintenance, and destabilization of N-Myc through Aurora A kinase inhibition reduces tumor burden. Our findings establish N-Myc as a driver of NEPC and a target for therapeutic intervention.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Xenograft Model Antitumor Assays
- Transduction, Genetic
- Recombinant Fusion Proteins
- Pyrimidines
- Proto-Oncogene Proteins c-myc
- Proto-Oncogene Proteins c-akt
- Protein Kinase Inhibitors
- Prostatic Neoplasms
- Phenylurea Compounds
- Orchiectomy
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Xenograft Model Antitumor Assays
- Transduction, Genetic
- Recombinant Fusion Proteins
- Pyrimidines
- Proto-Oncogene Proteins c-myc
- Proto-Oncogene Proteins c-akt
- Protein Kinase Inhibitors
- Prostatic Neoplasms
- Phenylurea Compounds
- Orchiectomy